Generic and Personalized RNAi-Based Therapeutics for a Dominant-Negative Epidermal Fragility Disorde...
Generic and Personalized RNAi-Based Therapeutics for a Dominant-Negative Epidermal Fragility Disorder
About this item
Full title
Author / Creator
Publisher
New York, NY: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
New York, NY: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Epidermolytic palmoplantar keratoderma (EPPK) is one of >30 autosomal-dominant human keratinizing disorders that could benefit from RNA interference (RNAi)-based therapy. EPPK is caused by mutations in the keratin 9 (KRT9) gene, which is exclusively expressed in thick palm and sole skin where there is considerable keratin redundancy. This, along wi...
Alternative Titles
Full title
Generic and Personalized RNAi-Based Therapeutics for a Dominant-Negative Epidermal Fragility Disorder
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1013921555
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1013921555
Other Identifiers
ISSN
0022-202X
E-ISSN
1523-1747
DOI
10.1038/jid.2012.28
